The evolution of the ophthalmology sector continued with last week’s news that Johnson & Johnson would pay $4.3 billion to acquire Abbott Medical Optics, the company’s ophthalmology surgery business.
The deal – if closed – promises to bring a newly engaged and energized Johnson & Johnson into ophthalmology. The company’s Vision Care business leads the contact lense business, but its presence in ophthalmologists offices has been minimal at best.
This deal clearly changes that.
In a conversation with OIS Podcast, Ashley McEvoy, group chairman of Johnson & Johnson’s Vision Care Group, lays out how the current AMO will fit into the future J&J; what leadership might look like and where the company might be looking for additional innovation.